The author, lee sheung
"my father was a new drug inventor." liu fei, founder of nanjing menover medicine, is a hero to her daughter。
This year, liu fei was born with a new drug developed by the team. China's down payment, the soluble injection drug certified by nmpa, is a boxing product that took over 10 years to develop in nanjing menovÍ medicine (known as “menowe medicine”), filling the gap in the country's non-surgery local fine-tuning area。
蓉芷® set up in 2013, reported clinically in 2015, obtained batches in 2017 and approved in 2025.” lew fei, the founder of the menowe medicines, has a long history of growth in the united states。
A painting by liu fei's daughter
Liu fei indicated that the menowe medicine is committed to a holistic solution, i. E. Focusing on two product lines — "the beauty of the heart" and "the beauty of the image" — and developing new medicines around mental illness and disfiguremental diseases, which are the heavy product in the area of disfigurement。
From a doctorate who focuses on scientific research to an entrepreneur who leads an enterprise to land, liu has walked a typical chinese scientist on a path of entrepreneurship and hopes to repair people’s faces and mental defects through technological innovation。
I'm starting three businesses with a core team
The story of liu fei began in an era when the chinese pharmaceutical industry was developing rapidly。
In 2007, the acoustic industry was listed at the new haven and became china's first chemical biopharmaceutical company in the united states. In the same year, liu fei graduated as a ph. D. In pharmacology from the chinese university of pharmacy and joined the anointed medicine industry。
Dr. Liu fei's dissertation in 2007
"i studied pharmacology, and during my doctorate i developed new molecules and one new drug. When he graduated, the innovation culture in the country was not too strong, with nine doctors in the same profession and seven in higher education, and i, as an i, thought that the college was going to look at it, went to the firm and wanted to learn to use it。
At the same time, it coincided with cooperation between the sound medicine industry and the university of qinghua. Following the company's arrangement, liu fei undertook a two-year postdoctoral study in qinghua, hoping to introduce the complex molecular structure developed by the faculty of chemistry at qinghua university into the structure of the drug molecules. And it is here that liu fei is gradually building up his thinking on productive research and transformation。
Following the completion of the post-doctoral work in 2009, liu fei returned to the acoustic industry to do pharmaceutical chemistry-related work and subsequently became director of the laboratory of pharmaceutical chemistry, working with a group of sea-level scientists to promote the development of new drugs for multiple targets。
The transition took place in 2012 with the launch of the "100s" platform by the acoustic industry to encourage internal teams to run out of business. This was a great opportunity for liu fei, then 33 years old, to start a business。
“me and my wife are in the same room as the doctor, and we are all conservative and do not like to take risks. But now that we're on the road to entrepreneurship, it's important to have experience. Life is a process, and it's always about results." liu fei said。
From left to right: liu fei's wife, liu fei's mentor, professor yoo kai winter, liu fei
Liu fei's business history is marked by the names of three businesses — nanjing sinothai medicine, nanjing norrit medicine, nanjing mejnowe medicine. He started a business that changed company names and shareholders, but the core team, the site, and even a lot of experimental equipment followed liu fei's “old man”。
Sinota medicine in nanjing is phase 1. 0 of its start-up. At that time, the company's core business consisted of providing innovative drug r & d services to other enterprises and generating income through the transfer of a batch of 3. 1 new drugs (the drug register classification, i. E. Unlisted drugs in the foreign market country)。
With a keen technical sense of smell, two new drug projects were transferred within a year from sinotaine in nanjing and the company survived successfully。
Phase 2. 0 of entrepreneurship was the creation of nanjing norret medicine with dr. Chen chi minh。
Dr. Chen started his business in the united states in 1993, and the company andrx, which was created and listed in nasdaq in 1996, is the top ten american generic pharmaceutical companies。
"we are in many places alike. For example, finding a new inspiration in product development makes you so excited that you can't sleep。
There was a rapid consensus that “innovativeness does not have to go from zero to one, combining drug chemistry and drug delivery systems, optimizing on the shoulders of giants, but is also a huge innovation”
To this end, norret has two orientations: first, to introduce new agent-type technologies from abroad to china, and second, to combine molecular structural innovation with drug delivery systems to create new technology platforms。
However, at the end of 2020, as dr. Chen chi minh's strategy was adjusted, he decided to narrow the front。
This gave liu fei a hard choice: to follow the “images” and stay in business or continue to fight with his team
"i still want to do something bigger for me." liu feitan said。
“the years 2017 to 2021 were the hottest years of financing new medicines, and many star companies are now dead. All who survive are capable of defeat." while liu fei was reminiscent of the epidemic, scientific research stopped and the team did not panic, but moved forward step by step, “all right, no adjustment, no special skills, no survival”
And that's what he wants for the team. Most of his team was under the lead of liu fei in 2007, working together for more than a decade and with a high degree of consistency。
The stage 3. 0 for entrepreneurship was the establishment of the nanjing menoway medicine in 2021。
“we have a three-pronged team with complementary capabilities. The responsibility for financing lies with the former director of investment, gotega, and for project management with the former colleagues. I'm in charge of making projects and technologies." liu fei is well aware of his character, “i am an i-person (introvert personality) infj (advocacy, commonly known as the green old man) and i prefer to concentrate on what i am good at.”
On the basis of past experience, liu fei and his team have tried cardiovascular, medical, psychiatric, tumours and, eventually, two tracks have surfaced: one mental illness and the other disfigured。
"we're summing up with "the beauty of the heart" and "the beauty of the image."。
Report card in the area of disfigured diseases
According to the medical aesthetics and cosmetology terminology (version 2015), a disfigured disease is defined as a disease that directly impairs the five official forms and functions of the person, or directly infringes the skin of the exposed part of the body and impairs the beauty of the person or the body。
"the elves' ears, the right horns' shoulders in the beauty of medicine make people look different. And what we do is help people deal with the appearance of illness or genetics and restore their health.” liu fei emphasizes this sense of boundaries。
Liu fei
In china, “over-fat” (commonly known as “two chins”) is an entirely new adaptation. There is no precedent at home, and once the solucose needle is set, everything starts from scratch。
The biggest challenge arises from the establishment of standards. “the faces of the americans and the chinese are completely different, their fat distributions and their jaws are different. We cannot apply the united states clinical standards directly.”
In order to define what is “fatful” in china, a set of lower-fat rating criteria (grades 0 to 4) has been introduced for chinese medicine, jointly with beijing co-operation and hospital. It takes a lot of effort to set standards。
In addition to clinical standards, there is also technical crumbling. The original product in the united states contains phenylethanol as a preservative, but this ingredient has an irritant and sensitization risk. Can you do "best in the world"? It also poses a high challenge to the technical team。
Another question needs to be answered when the product is coming to life: swelling。
In overseas markets, swelling after injection has been the focus of patients ' complaints。
But liu fei believes that this is the externalization of the product. “swollenness is a local inflammation caused by the dissolution of fat cells. This inflammation involves the collection of fibre cells and the stimulation of gelatin protein generation. When we were doing phase iii, we specifically added the "suspense" indicator. The results show that half of the population is lax and the other half is tighter. If the pursuit is completely unswollen, it may lead to a lax skin. Because without inflammation, the glue won't regenerate."
Such counter-intuitive scientific findings require significant market education costs. But in liu's eyes, this is precisely the opportunity for menover's medicine: not just to sell it, but to set a standard of “serious medical care”。
Liu fei revealed that, although the market was strong after the approval, the company was not in a hurry to lay the goods. "our product is medicine, not equipment. Injecting effects and side effects are highly technical for doctors, who must be trained to avoid negative effects due to operational problems.”
In order to implement this concept, the current clients of the menowe medicine are mainly limited to formal medical facilities in the head。
At the same time, menowey medicine has established a medical team dedicated to the certification and training of doctors. “we need to explain the medical logic and tell you what fatty problems can be solved by sofa needles. While compliance products are costly, safety and effectiveness are long-term values.” liu fei said。
The meenover medical team
In the field of disfigured diseases, the menoway medicine programme is designed to create a matrix of “pharmaceutical-army-making” products around medicines。
At present, a number of local soluble products of the menowe medicine are being developed, specialized in instruments and cosmetics at the “minova” company, which has no sieves, providing post-operative dressing and tight products around “circle aesthetics”。
From two tracks to multiple tracks
Scientists start businesses, with a little heroism in their bones。
"our location is "first in china, best in the world." liu fei said。
Over the past decade or so, the chinese medical-american market has gone through a period of brutal growth. Liu fei describes the past market as “disturbed to subversive awareness”。
"many are no products, and a story can sell at high prices." the example of liu fei is: there are brand brochures with the "recommendant of the french star" and the map is an italian national-class actor; there are also large numbers of chinese registered shell companies abroad to sell domestically produced products for export, turning them into "french" korean production。
“more exaggerated is the fact that some illegal brands are not registered even with trademarks and can be produced by anyone. The agency asked, "whatever the product is, it doesn't answer."
In this environment, it is both a barrier and an opportunity for the menowe medicine to insist on innovative medicines。
“the year 2025 is a turning year for upstream medical enterprises.” liu fai analytics, “the former chinese health-care dividend was the `middle-out gap' — there were good things abroad, not at home, that could be sold. And now there's something abroad, there's almost everything in the country, and it's even starting to roll. The next few years are bound to be special, with businesses that can survive, either technically or brandly. But to get all illicit products out of the market is not something that can be done in a year or two, but at the core is market education.”
He further stressed that “the ultimate quest of the human person is not only for healthy survival but also for `quality survival'. It is also a mission to make life-saving life-saving drugs, which used to be on tumours, to make life-saving drugs, to make people look better, to make them feel happier and to be able to live with dignity and quality.”
If the solucose needle is a spear already taken by the menot, the psychopharmaceutical medicine is a shield for its future。
This company, which does soluble needles, is also making antidepressants. In liu fei's logic, the two are highly comfortable at the bottom of technical and commercial logic。
Commercially, both have strong market demand. “the market for mental illness in europe and the united states is large, and in recent years there has been much social pressure and mental problems in china. You have a sense of treatment for depression."
The new anti-post-natal depression mi078 capsule of the menowe medicine is the product of this logic. “three clinical sessions at the end of 2025, expected to be listed in 2028.” liu fei indicates。
In addition, liu fei has focused on the more immediate needs: “young people's association is now becoming more and more afraid, and companies in the united states are already working on acutely threatening drugs. It's all in the realm of serious medicine, and it's where we're going.”
The meenover medicine's on the line
To date, in addition to soluble, depression, the mercantiles in the tube include hair loss, light aging, scarring, diabetes。
“we drug people, especially new ones, are a little heroic. We want everyone to relax and make the world a little more beautiful, even a little bit, that's enough.” liu fei said so。
